Dynamis Pharmaceuticals
Dynamis Pharmaceuticals is a privately held, development-stage biopharmaceutical company founded in 1997 and based in Jenkintown, Pennsylvania, that develops proprietary small-molecule drugs targeting chronic inflammatory diseases. It operates with a 51-100 employee headcount typical of early-stage biotech.
- Company typePrivate
- Founded1997
- HeadquartersJenkintown, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Dynamis Pharmaceuticals firmographics
Firmographics- Name
- Dynamis Pharmaceuticals
- Website
- https://dynamis-therapeutics.com
- Company type
- Private
- Founded year
- 1997
- Headcount range
- 1–10 employees
- Short description
- Dynamis Pharmaceuticals is a privately held, development-stage biopharmaceutical company founded in 1997 and based in Jenkintown, Pennsylvania, that develops proprietary small-molecule drugs targeting chronic inflammatory diseases. It operates with a 51-100 employee headcount typical of early-stage biotech.
- Ownership category
- akta.pro rank
Dynamis Pharmaceuticals industry classification
Industry- Product category
- Inflammatory Disease Therapeutics
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
Keywords
Where Dynamis Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Jenkintown
- HQ country
- United States
- HQ region
- North America
Markets served
Dynamis Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Dynamis Pharmaceuticals product offering
Product offeringCore offering
Dynamis Pharmaceuticals is a biopharma company developing proprietary small molecule drugs to treat chronic inflammatory diseases. The firm focuses on small-molecule drug discovery and development intended for eventual therapeutic use in chronic inflammation indications. As of the available information, no commercially launched or named product candidates are disclosed.
Differentiator
Problem solved
Functional benefit
Companies that use Dynamis Pharmaceuticals
Customer profileIdeal customer profiles1 record
Dynamis Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Dynamis Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Amgen: Large biotech with Enbrel, Otezla (acquired via Horizon Therapeutics), and Tavneos (via ChemoCentryx) in chronic inflammation. Strategic acquirer of small-molecule inflammation assets analogous to what Dynamis may seek.
- Bristol-Myers Squibb: Major pharma with established inflammation and immunology portfolio (e.g., Zeposia in ulcerative colitis and MS). Relevant broad incumbent in the chronic inflammation therapeutic area.
- AbbVie: Global biopharma with Humira, Skyrizi, and Rinvoq dominating chronic inflammatory disease treatment. Relevant incumbent benchmark for the therapeutic area Dynamis targets, though vastly larger and more diversified.
- Pfizer: Major pharma with Xeljanz (tofacitinib) and Cibinqo (abrocitinib) oral JAK inhibitors for inflammatory diseases. Sets the competitive bar for oral small molecules in Dynamis's chosen space.
- Eli Lilly: Major pharma with Taltz and Olumiant for inflammatory diseases and a strong record of in-licensing and acquiring small-molecule assets. Comparable large-pharma competitor/partner for an inflammation-focused small molecule.
Direct peers
- ChemoCentryx: Small-molecule drug developer focused on autoimmune and inflammatory diseases (Tavneos for ANCA-associated vasculitis), acquired by Amgen in 2022. Comparable as a small-cap inflammation-focused small-molecule biotech.
- Ardea Biosciences: Pre-revenue small-molecule biotech developing therapies for inflammatory and metabolic diseases (lesinurad for gout), acquired by AstraZeneca. Analogous small-molecule inflammation focus and small private-company trajectory.
- Galapagos NV: Clinical-stage biopharma developing small-molecule JAK1 inhibitors (e.g., filgotinib) for chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. Highly comparable modality, target indication, and small-molecule focus to Dynamis.
- Prometheus Biosciences: Clinical-stage immunology and inflammatory bowel disease biotech acquired by Merck in 2023 for ~$11B. Comparable as a focused inflammation therapeutics company whose trajectory illustrates both the upside and the capital intensity of the space.
Regional players
- Arcturus Therapeutics: Although primarily RNA-focused and California-based, Arcturus is a comparable small-cap public biotech with limited inflammation assets that illustrates the capital-raise challenges facing small private inflammation companies seeking to scale.
Market position
Customer concentration
Dynamis Pharmaceuticals social profiles
Digital presenceDynamis Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dynamis Pharmaceuticals leadership team
Management profileNumber of profiles
Dynamis Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dynamis Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dynamis Pharmaceuticals
What does Dynamis Pharmaceuticals do?
Dynamis Pharmaceuticals is a biopharma company developing proprietary small molecule drugs to treat chronic inflammatory diseases. The firm focuses on small-molecule drug discovery and development intended for eventual therapeutic use in chronic inflammation indications. As of the available information, no commercially launched or named product candidates are disclosed.
When was Dynamis Pharmaceuticals founded?
Dynamis Pharmaceuticals was founded in 1997. It employs 1 to 10 people.
Where is Dynamis Pharmaceuticals based?
Dynamis Pharmaceuticals is headquartered in Jenkintown, United States, in the North America region.
Who are Dynamis Pharmaceuticals's main competitors?
Broad incumbents on record are Amgen, Bristol-Myers Squibb, AbbVie, Pfizer and Eli Lilly. Direct peers are ChemoCentryx, Ardea Biosciences, Galapagos NV and Prometheus Biosciences. Arcturus Therapeutics is listed as a regional player.
Does Dynamis Pharmaceuticals have an API?
No public API is recorded for Dynamis Pharmaceuticals.
What industry is Dynamis Pharmaceuticals in?
Dynamis Pharmaceuticals's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 54171 and its SIC code is 2834.